Ramalingam’s lab is interested in the area of curative genome editing therapies with the ultimate goal of establishing tools for enabling cell and gene therapy. To accomplish this, his lab is adopting an interdisciplinary strategy to develop alternate therapy models, primarily for inherited blood disorders and hematological malignancies.
We are currently running three different research programs:
Induced pluripotent stem cell-based human disease model to study disease biology
Curative genome-editing therapies for inherited blood disorders
Development of next-generation novel CAR systems and off-the-shelf CAR-T cell immunotherapies.
Development of pathophysiologically relevant models of sickle cell disease and β-thalassemia for therapeutic studies
